Estrogen‐metabolizing gene polymorphisms in the assessment of breast carcinoma risk and fibroadenoma risk in Caucasian women
Open Access
- 14 June 2004
- Vol. 101 (2) , 264-269
- https://doi.org/10.1002/cncr.20361
Abstract
BACKGROUND Genes encoding enzymes involved in estrogen metabolism are held to be candidate genes for associations with breast disease. In these candidate genes, no critical combination of single-nucleotide polymorphisms (SNPs) for assessing breast carcinoma risk has been reported to date. METHODS In a large case–control study, the authors investigated 10 estrogen-metabolizing SNPs in 396 patients with breast carcinoma, 154 patients with fibroadenoma, and 1936 healthy control patients without breast carcinoma in their personal history. The following 10 SNPs were analyzed using sequencing-on-chip technology via a solid-phase polymerase chain reaction assay performed on oligonucleotide microarrays: catechol-O-methyltransferase Val158Met G→A, 17-beta-hydroxysteroid dehydrogenase type 1 vIV A→C, cytochrome P-450 (CYP) family 17 A2 allele T→C, CYP1A1-1 MspI restriction fragment length polymorphism (RFLP) T→C, CYP1A1-2 Ile462Val A→G, CYP19-1 Trp39Arg T→C, CYP19-2 Arg264Cys C→T, CYP19-3 Cys1558Thr C→T, steroid-5-alpha reductase type 2 Val89Leu G→C, and vitamin D receptor BsmI RFLP. A total of 21,350 genotypes were evaluated. Associations and two-way interaction models were calculated using stepwise logistic regression. RESULTS In a multiple model, CYP1A1-1 (P = 0.004) and CYP1A1-2 (P = 0.03) were found to be associated with significantly decreased and increased risks of breast carcinoma, respectively. When two-way interactions involving investigated SNPs were ascertained, no significant interactions among polymorphisms were noted. Comparison of patients with fibroadenoma with control patients revealed significantly increased and decreased risks of fibroadenoma when the mutant alleles of CYP17 (P = 0.02) and CYP1A1-1 (P = 0.04), respectively, were present. CONCLUSIONS The authors obtained the first SNP data indicating that CYP17 and CYP1A1-1 play a role in the pathogenesis of fibroadenoma. Although the authors were not able to develop interaction models involving SNPs, they did provide evidence that CYP1A1 is a low-penetrance susceptibility gene with respect to breast carcinoma in a large series of Caucasian women. Cancer 2004. © 2004 American Cancer Society.Keywords
This publication has 17 references indexed in Scilit:
- Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast CancerJournal of Clinical Oncology, 2003
- Estrogen-Metabolizing Gene Polymorphisms, But Not Estrogen Receptor-α Gene Polymorphisms, Are Associated with the Onset of Menarche in Healthy Postmenopausal Japanese WomenJournal of Clinical Endocrinology & Metabolism, 2003
- Population Screening in the Age of Genomic MedicineNew England Journal of Medicine, 2003
- Polymorphisms in Steroid Hormone Pathway Genes and Mammographic DensityBreast Cancer Research and Treatment, 2003
- CYP1A1, GSTM1, and GSTT1 polymorphisms and breast cancer risk in Brazilian womenCancer Letters, 2002
- Accessing Single Nucleotide Polymorphisms in Genomic DNA by Direct Multiplex Polymerase Chain Reaction Amplification on Oligonucleotide MicroarraysAnalytical Biochemistry, 2002
- Polymorphisms in CYP1A1 and smoking: no association with breast cancer riskCarcinogenesis: Integrative Cancer Research, 2001
- Multifactor-Dimensionality Reduction Reveals High-Order Interactions among Estrogen-Metabolism Genes in Sporadic Breast CancerAmerican Journal of Human Genetics, 2001
- Genetic variants of CYP19 (aromatase) and breast cancer riskOncogene, 2000
- New Role for Estrogen in Cancer?Science, 1998